IP Library Granted Patent US 10,005,743
Granted Patent B2
US 10,005,743 · App. 15/192,098 · Granted Jun 26, 2018

Methods for producing viloxazine salts and novel polymorphs thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,005,743
App. No.
15/192,098
Granted
Jun 26, 2018
Kind
B2
Abstract

Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

Claims (17)

1. A method of manufacturing N-benzyl viloxazine or a pharmaceutically acceptable salt thereof, the method comprising:

(a) reacting a compound of formula

with N-benzyl-aminoethanol to form a diol compound of formula

(b) contacting the diol compound in a solvent system with a base to generate a basic system; and,

(c) contacting the basic system with a cyclization agent to produce N-benzyl viloxazine having the following formula:

wherein Et is an ethyl group and Bn is a benzyl group.

2. The method according to claim 1 , wherein a phase transfer catalyst is utilized in step (c).

3. The method according to claim 2 , wherein the phase transfer catalyst is benzyltriethylammonium chloride.

4. The method according to claim 1 , wherein the solvent system is a liquid-liquid biphasic system or a monophasic liquid system.

5. The method according to claim 4 , wherein the solvent system is a liquid-liquid biphasic system.

6. The method according to claim 5 , wherein the liquid-liquid biphasic system comprises water.

7. The method according to claim 4 , wherein the solvent system is a monophasic liquid system.

8. The method according to claim 7 , wherein the monophasic liquid system comprises toluene.

9. The method according to claim 1 , wherein the base is a solid.

10. The method according to claim 9 , wherein the base is sodium hydroxide.

11. The method according to claim 1 , wherein the cyclization agent is a sulfonyl halide selected from the group consisting of tosyl chloride, brosyl chloride, nosyl chloride, and mesyl chloride.

12. The method according to claim 1 , wherein the cyclization agent is toluenesulfonyl chloride and the solvent system is a liquid-liquid biphasic system.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 044552/0694 →